Investors piled into the initial public offering of Supriya Lifescience Ltd., a bulk drugmaker, on the final day.
The IPO—which comprised a fresh issue worth Rs 200 crore and an offer for sale of up to Rs 500 crore—was subscribed 71.47 times at the end of day three.
The company was selling shares at Rs 265-274 apiece, seeking a market value of Rs 2,205 crore at the upper end. The promoter and promoter group shareholding will fall to 68.24% after the share sale from close to 100% now.
Prior to the IPO, Supriya Lifescience had raised Rs 315 crore from anchor investors by allotting 1.15 crore shares at Rs 274 apiece.
BNP Paribas Arbitrage, Societe Generale, Reliance General Insurance Company, Aditya Birla Sun Life Insurance Company, Kuber India Fund, Saint Capital Fund and Nippon India Mutual Fund are among the anchor investors.
Subscription Details: Day 3
The IPO was subscribed 71.47 times at 5:00 p.m. on Dec. 20.
Institutional investors: 31.83 times.
Non-institutional investors: 161.22 times.
Retail investors: 55.75 times.
Research Reports On Supriya Lifescience
Supriya Lifescience IPO - Focused Player In Key, Niche Active Pharma Ingredients: ICICI Direct
Supriya Lifescience IPO - Investment Rationale, Financials, Risks, Concerns: Motilal Oswal
Supriya Lifescience IPO - Valuations, Strengths, Key Strategies, Risks: Anand Rathi
Watch BloombergQuint's IPO Adda With Supriya Lifescience's Management
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
